Natco Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1479.3, up 2.32% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 1.01% on the day, quoting at 23954.849609375. The Sensex is at 79251.13, down 1.16%. Natco Pharma Ltd has gained around 7.61% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has gained around 4.06% in last one month and is currently quoting at 22314.55, up 1.38% on the day. The volume in the stock stood at 9.96 lakh shares today, compared to the daily average of 6.58 lakh shares in last one month.The PE of the stock is 14.09 based on TTM earnings ending September 24.Powered by Capital Market - Live

Natco Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1429.95, up 1.05% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Natco Pharma Ltd has added around 1.49% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has added around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 7.85 lakh shares today, compared to the daily average of 7.49 lakh shares in last one month.The PE of the stock is 13.78 based on TTM earnings ending September 24.Powered by Capital Market - Live

The drug maker stated that since no business operations are carried out on the said land and building being sold, the sale will not have any impact on the business operations of the company. Further, the sale of the said property does not constitute an undertaking or substantially the whole of the undertaking for the company in terms of Section 180(1)(a) of the Companies Act, 2013. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India, which cater to both domestic and international markets, including regulated markets like the United States of America and Europe. The company's consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.11% to currently trade at Rs 1,362.65 on the BSE.Powered by Capital Market - Live

Natco Pharma today announced submission of Abbreviated New Drug Application (ANDA) with USFDA  for Risdiplam for Oral Solution. NATCO believes it is amongst one of the first two companies to have filed a substantially-complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. NATCO has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. EVRYSDI' has recorded sales of USD 571 million in the US market for the year 2023. Risdiplam for Oral Solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.Powered by Capital Market - Live

The ANDA is a generic version of Evrysdi (Risdiplam) for oral solution by Genentech Inc. Risdiplam for oral solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. The drug maker believes it is amongst the first two companies to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. The company has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc. Evrysdi has recorded sales of $571 million in the US market for the year 2023. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like the United States of America and Europe. The company's consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24. The scrip rose 0.64% to currently trade at Rs 1,374.95 on the BSE.Powered by Capital Market - Live

Natco Pharma has fixed 27 November 2024 as record date for taking on record of its shareholders eligible for the purpose of payment of second interim dividend. The dividend will be paid from 04 December 2024. Powered by Capital Market - Live

Natco Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1376.75, down 1.01% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Natco Pharma Ltd has eased around 3.09% in last one month.Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 15.6 lakh shares today, compared to the daily average of 4.86 lakh shares in last one month.The PE of the stock is 16.23 based on TTM earnings ending June 24.Powered by Capital Market - Live

Net profit of Natco Pharma rose 83.55% to Rs 677.30 crore in the quarter ended September 2024 as against Rs 369.00 crore during the previous quarter ended September 2023. Sales rose 32.94% to Rs 1371.10 crore in the quarter ended September 2024 as against Rs 1031.40 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1371.101031.40 33 OPM %58.6644.41 - PBDT864.00483.20 79 PBT818.20439.60 86 NP677.30369.00 84 Powered by Capital Market - Live

Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 November 2024, inter alia, have recommended the second interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Revenue from operations was at Rs 1,371.1 crore in Q2 FY25, up 32.93% from Rs 1,031.4 crore posted in Q2 FY24. The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharma business. Total income jumped 35.26% year on year to Rs 1,434.9 crore in the quarter ended 30 September 2024. Profit before tax in Q2 FY25 stood at Rs 818.20 crore, up 86.12% as against Rs 439.60 crore reported in the same period a year ago. The company's revenue from API stood at Rs 49.6 crore (down 36.24% YoY), income from domestic formulations was at Rs 102.3 crore (down 0.19% YoY) and revenue from crop health sciences (CHS) came in at Rs 14.1 crore (down 74.73% YoY) during the period under review. On the other hand, revenue from exports formulations jumped 52.88% YoY to Rs 1,211.3 crore during the quarter. Meanwhile, the company's board declared a second interim dividend of Rs 1.50 per equity share in FY25. The record date for the same is fixed on Monday, 25 November 2024. The payment of the dividend will start from 2 December 2024. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe. Powered by Capital Market - Live